IN THE CLAIMS:

B1

1. (Currently Amended) A method of treating a wound in an animal or human comprising administering to said animal or human a pharmaceutical composition comprising a lipopeptide or lipoprotein with the following general structure:



wherein

R^1 and R^2 stand for C_{7-25}-alkyl, C_{7-25}-alkenyl or C_{7-25}-alkinyl,

X is S, O, or CH_2,

Z^1 and Z^2 stand for H or methyl,

W stands for CO or $S(O)_n$ (where n = 1 or 2) and

Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acid residues and the asymmetric carbon atom marked with * has the absolute configuration S when X = S (sulfur).

2. (Currently Amended) The method of Claim 1, wherein Y comprises an amino acid sequence consisting of 1 to 25 amino acids.

3. (Currently Amended) The method of Claim 1, wherein Y comprises an amino acid sequence which is selected from the group consisting of:

(i) amino acid sequence, which does not have an adverse influence on the water solubility of the lipopeptide or lipoprotein;

(ii) GQTNT (SEQ ID NO:1):

(iii) SKKKK (SEQ ID NO:2);

Cont B1

(iv) GNNDESNISFKEK (SEQ ID NO:3);

(v) GQTDNNSSQSQQPGSGTTNT (SEQ ID NO:4);

or a fragment or variant of the amino acid sequences in (ii), (iii), (iv) and (v) wherein said fragment or variant has macrophage stimulating activity.

4. (Currently Amended) The method of claim 1 wherein the C_{7-25}-alkyl, C_{7-25}-alkenyl, or C_{7-25}-alkinyl is a C_{15}-alkyl, C_{15}-alkenyl or C_{15}-alkinyl, respectively.

5. (Currently Amended) The method of claim 1 wherein the double bond(s) in the C_{7-25}-alkenyl group has(have) the cis-configuration.

6. (Currently Amended) A method of treating a wound in an animal or human comprising administering to an animal or human a physiologically compatible lipopeptide or lipoprotein which carries at the N-terminal a dihydroxypropyl cysteine group with two, fatty acids bonded via ester bonds.

7. (Currently Amended) The method of claim 1 wherein said lipopeptide or lipoprotein [obtainable] is obtained from a mycoplasma clone.

8. (Currently Amended) The method of Claim 7, wherein said lipopeptide or lipoprotein is obtained from a *Mycoplasma fermantans* clone.

9. (Currently Amended) The method of claim 1 wherein said the lipopeptide or lipoprotein is water-soluble or amphoteric.

10. (Currently Amended) The method of claim 1 wherein said lipopeptide or lipoprotein selected from the group consists of:

(i) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GQTNT (SEQ ID NO:5)

(ii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-SKKKK (SEQ ID NO:6)

(iii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GNNDESNISFKEK (SEQ ID NO:7)

(iv) S-[2,3-bispalmitoyloxy-(2S)-propyl]cysteinyl-GNNDESNISFKEK (SEQ ID NO:8) and

Cont B1

(v) S-[2,3-bispalmitoyloxypropyl]cysteinyl-

GQTDNNSSQSQQPGSGTTNT (SEQ ID NO:9)

11. (Currently Amended) The method of claim 1 wherein said lipopeptide or lipoprotein is in the form of a solution for epicutaneous application, an injection solution, a salve, a lotion, an aqueous suspension, a plaster impregnated or coated with said lipopeptide or lipoprotein, encapsulated in liposomes, or coupled to biodegradable carrier polymers.

12. (Currently Amended) The method of claim 1 wherein said wound is a wound after injury or surgical intervention, a chronically infected wound, a burn wound, a chronic, *Ulcus venosum*, or a wound of a patient who is corpulent or diabetic or are subjected to radiation or chemotherapy.

13. (New) The method of claim 1 wherein R^1 and R^2 and the same.

14. (New) The method of claim 1 wherein R^1 and R^2 are different.

15. (New) The method of claim where Z^1 and Z^2 are the same.

16. (New) The method of claim where Z^1 and Z^2 are different.

17. (New) The method of claim 6 wherein said fatty acids are long-chain fatty acids.

18. (New) The method of claim 6 wherein said fatty acids are the same.

19. (New) The method of claim 6 wherein said fatty acids are different.